Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Osimertinib Then Chemotherapy in EGFR-mutated Lung Cancer with Osimertinib Third-line Rechallenge

NCT04335292 is registered in ClinicalTrials.gov with Mark Vincent as lead sponsor.

NCT NCT04335292
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04335292 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Osimertinib Then Chemotherapy in EGFR-mutated Lung Cancer with Osimertinib Third-line Rechallenge
Lead sponsor
Mark Vincent
Phase
Phase 2
Overall status
Recruiting
Start date
January 6, 2021
Completion date
June 1, 2027
Enrollment
200 (estimated)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung cancer